[{"orgOrder":0,"company":"Palatin Technologies","sponsor":"AMAG Pharmaceuticals","pharmaFlowCategory":"D","amount":"$16.3 million","upfrontCash":"$12.0 million","newsHeadline":"AMAG Pharmaceuticals Completes Divestment of Women\u2019s Health Assets","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"July 2020","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Cosette Pharma","pharmaFlowCategory":"D","amount":"$171.0 million","upfrontCash":"$12.0 million","newsHeadline":"Palatin Completes Sale of Vyleesi\u00ae to Cosette Pharmaceuticals for up to $171 Million","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"December 2023","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Cosette Pharma","pharmaFlowCategory":"D","amount":"$171.0 million","upfrontCash":"$12.0 million","newsHeadline":"Palatin Completes Sale of Vyleesi to Cosette Pharmaceuticals for up to $171 mn","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"January 2024","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Cosette Pharma","pharmaFlowCategory":"D","amount":"$171.0 million","upfrontCash":"$12.0 million","newsHeadline":"Cosette Pharmaceuticals Acquires Vyleesi\u00ae (Bremelanotide Injection) from Palatin Technologies Inc.","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"January 2024","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Palatin Announces Publication of Vyleesi\u00ae (bremelanotide) fMRI Study in Women with Hypoactive Sexual Desire Disorder (HSDD)","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase IV","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"October 2022","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase IV"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Palatin Initiates Enrollment in The Phase 2 Bremelanotide Breakout Study in Patients with Diabetic Kidney Disease","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"January 2023","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase II"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Fosun Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Palatin's Vyleesi\u00ae Licensee Fosun Pharma Reports First Commercial Sale in China and South Korean Licensee Kwangdong Pharmaceuticals Completes Enrollment in Phase 3 Clinical Study","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"August 2023","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Palatin Initiates Clinical Program for Bremelanotide Co-Formulated with a PDE5i for the Treatment of ED in Patients Non-Responsive to PDE5i Treatment","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"August 2023","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Palatin Announces FDA Clearance of IND Application for the Co-Administration of Bremelanotide with Tirzepatide (GLP-1) for the Treatment of Obesity","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"May 2024","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I"}]
Find Clinical Drug Pipeline Developments & Deals for Bremelanotide
PT-141 (bremelanotide) is a melanocortin receptor 4 agonist (MCR4), which is being evaluated in combination with tirzepatide for the treatment of obesity.
Through the divestment, Cosette will further expand its women's health platform by adding Vyleesi (bremelanotide acetate), the first and only as-needed treatment approved for premenopausal women with acquired, generalized hypoactive sexual desire disorder.
Through the divestment, Cosette will further expand its women's health platform by adding Vyleesi (bremelanotide acetate), the first and only as-needed treatment approved for premenopausal women with acquired, generalized hypoactive sexual desire disorder.
Through the divestment, Cosette will further expand its women's health platform by adding Vyleesi (bremelanotide acetate), the first and only as-needed treatment approved for premenopausal women with acquired, generalized hypoactive sexual desire disorder.
Vyleesi (bremelanotide injection) is a melanocortin receptor (MCR) agonist that is indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder.
Vyleesi (bremelanotide injection) is a melanocortin receptor (MCR) agonist that is indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder.
BMT-701 (bremelanotide) is a synthetic peptide analogue of melanocyte stimulating hormone alpha (MSHα), and its metabolism is by hydrolysis of amide bonds and digestion by cellular peptidases.
Vyleesi (bremelanotide) is the first and only as-needed treatment approved by the FDA for premenopausal women with acquired, generalized Hypoactive Sexual Desire Disorder (HSDD).
Under the terms of the termination agreement, all of AMAG’s rights and obligations to develop and commercialize Vyleesi under the license agreement will terminate, and full ownership of Vyleesi will transfer back to Palatin.